Status:
COMPLETED
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month exten...
Eligibility Criteria
Inclusion
- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.
Exclusion
- Previous enrollment in another Allergan Bimatoprost SR Study.
- Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
- Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration
- History of glaucoma surgery
Key Trial Info
Start Date :
December 15 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 19 2019
Estimated Enrollment :
594 Patients enrolled
Trial Details
Trial ID
NCT02247804
Start Date
December 15 2014
End Date
July 19 2019
Last Update
June 11 2020
Active Locations (106)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Glaucoma Specialists
Phoenix, Arizona, United States, 85050
2
Lugene Eye Institute
Glendale, California, United States, 91205
3
Lakeside Vision Center
Irvine, California, United States, 92604
4
Hamilton Glaucoma Center, Shiley Eye Center UCSD
La Jolla, California, United States, 92037